When most of the companies in the pharmaceutical and other related fields are struggling to sustain their profitability, PDL BioPharma Inc (NASDAQ:PDLI) has ended another quarter and year on a high note. As per the reports, it announced financial results for the recently concluded the year 2015. The yearly revenue figure surpassed $590.4 million figure.

Insights of Financial Data

In 2014, PDL’s total revenues were $581 million. Given that the market hasn’t reacted favorably for most of the time, this growth in revenues from $581 million to $590 million is appreciable. Out of 2015’s total revenues, $485.2 million belonged to royalty received as license fees. PDL deals in many products; however, increased income in the year 2015 was driven mainly by the sales of Xolair, Perjeta, and Kadcyla.

When it comes to fourth quarter results, PDL’s revenues increased to $178.1 million as compared to $117.1 million in 4Q2014. Out of the total revenue figure, license fees covered a significant portion with $121.2 million. The estimated fair value of PDL’s primary royalty rights asset Depomed, Inc., increased during the fourth quarter, which affected the overall revenue position in a positive way.

Operating expenses for the year were $40.1 million as compared to $34.9 million in 2014. When it comes to net income for the year, PDL reported a whopping figure of $332.8 million or $2.03 per share as compared to net income of $332.2 million or $1.86 per share in 2014. Net income in 4Q2015 was $100.6 million against $55.1 million during the same period in 2014.

PDL generated total cash of $301.5 million from operating activities in 2015 as compared to $292.3 million during the same period in the year 2014. Despite all the excellent income and revenue figures, PDL’s cash and cash equivalent were $220.4 million at the end of 2015, compared to $293.7 million at the end of December 2014.

Going forward, it will look forward to taking many initiatives to attain profitable situation, details of which will be announced in the near future.

Previous articleZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s Net Loss Decreased To $9.5 Million In 4Q2015 Amid Growing Market Uncertainty
Next articleVerastem Inc (NASDAQ:VSTM) Shifts Focus To Core Treatments After Net Loss Reached To $57.9 Million In 2015
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.